Drugs / DA-2803-R
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05957380 | Mar 2023 → Sep 2024 | hepatitis B virus infection | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DA-2803-R | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05957380 ↗ |
| Route | Oral | “All participants are administered one tablet per day for 48 weeks” NCT05957380 ↗ |